A Study of LY900010 (LY2452473 + Tadalafil) in the Treatment of Men With Erectile Dysfunction.
Phase of Trial: Phase II
Latest Information Update: 06 May 2015
At a glance
- Drugs Tadalafil; TT 701
- Indications Erectile dysfunction
- Focus Therapeutic Use
- 06 May 2015 Results (effects on lean body mass) published in Transition Therapeutics media release; Transition Therapeutics has licensed the rights for TT701 from Eli LIlly.
- 16 Dec 2011 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
- 16 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.